text:
|Publication number
|Publication type
|Application number
|Publication date
|Mar 31, 1992
|Filing date
|Apr 6, 1987
|Priority date
|Apr 6, 1987
|Fee status
|Publication number
|Pablo Rubinstein, Margaret Nichols
|Original Assignee
|New York Blood Center, Inc.
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (3), Non-Patent Citations (37), Referenced by (9), Classifications (21), Legal Events (5)
|External Links: USPTO, USPTO Assignment, Espacenet
1. Field of the Invention
The present invention relates to a monoclonal antibody which identifies the human blood group Fyab of the Duffy system and the use of such monoclonal antibody to provide protection against P. vivax malaria infection by eliciting anti-idiotypic antibodies.
2. Background Information
Malaria is the most prevalent infectious disease of mankind. Its widespread geographic distribution together with the severe pathologic consequences of the infection make malaria a major medical and financial burden for many of the developing nations.
Its enormous prevalence and the clinical severity of is effects underlie its biological consequences as a natural selection agent. It has been shown that the frequency of the sickle-cell trait increases in areas of high malarial endemia, owing to the resistance of red cells from Ss heterozygous individuals against the successful multiplication of intracellular forms of the malarial parasite (A. C. Allison, "Polymorphism and Natural Selection in Human Populations", Cold Spring Harbor Sympos., Quant. Biol., 29, 137, (1964)). This is true in spite of the gene frequency decrease caused by the invariably early lethality of the homozygous form of sickle cell disease in nature (Allison, supra and M. J. Friedman, "Oxidant Damage Mediates Variant Red Cell Resistance to Malaria", Nature, 280, 245, (1979)).
There are several different kinds of malaria, one of which is caused by the parasite P. vivax, which attacks the red blood cells of susceptible individuals. A genetic trait of special interest with regard to P. vivax is the absence of antigens encoded by the blood group system called Duffy (F. B. Livingston, "The Duffy Blood Groups, Vivax Malaria and Malaria Sections in Human Populations: Review", Human Biol., 56, 413, (1984)). It has been shown that individuals whose red blood cells lack the product of the Duffy genes are not susceptible to the penetration of P. vivax owing to the fact that Duffy molecules serve as the receptor for the parasite (L. H. Miller, H. J. Mason, D. F. Clyde and M. H. McGinnis, "The Resistance Factor to Plasmodium Vivax in Blacks, The Duffy Blood Group Genotype (a-b-)", N. Engl. J. Med., 295, 302, (1976)).
The sporozoan protozoa of the genus Plasmodium are pigment-producing ameboid intracellular parasites of vertebrates, with one habitat in red blood cells and another in cells of other tissues. There are at least five species of plasmodia that may infect humans, one of which is Plasmodium vivax ("P. vivax").
Malarial parasites are transmitted from host to host by blood sucking females of several species of the genus Anopheles. It is in the mosquito that the sexual phase of the life cycle of P. vivax takes place leading to the production of sporozoites. After their introduction into a "new" host, these sporozoites reside in the parenchymal cells of the liver and multiply asexually causing the eventual rupture of the hepatic cells and the release of the asexual forms (merozoites) into the blood stream. There they actively penetrate into red blood cells in a nearly synchronous fashion and because the rate of growth and cell division of P. vivax merozoites is essentially identical, the infected erythrocytes simultaneously reach the stage of parasite load at which they break. This produces the typical cycles of fever every 48 hours, hence the name of Tertian malaria.
P. vivax infection may persist without treatment for as long as five years. P. vivax parasitemias are relatively low-grade, primarily because the parasites favor either young or old red blood cells, but not both.
Immunity to P. vivax is commonly only partial in nature, which allows the occurrence of super infections that evolve independently causing an overlap in the cycles of parasite release leading to the appearance of fever in shorter cycles. P. vivax exhibits considerable antigenic "diversity" and "variation", as do other malarial Plasmodia (M. Hommel, "Antigenic Variation in Malaria Parasites", Immunology Today, 6, 28, (1985)), although it has been recently shown that antigenic components of P. vivax sporozoites exist that are common to parasites from different isolates (F. Zavala, A. Masuda, P. M. Graves, V. Nussenzweig and R. Nussenzweig, "Ubiquity of the Repetitive Epitope of the CS Protein in Different Isolates of Human Malaria Parasites", J. Immunol , 135, 2790, (1985)).
"Diversity" refers to phenotypic differences between different isolates of the same species and is accompanied by isolate-specific differences in neoantigens appearing on the surface of infected erythrocytes (M. Hommel, P. H. David and L. D. Oligino, "Surface Alterations of Erythrocytes in Plasmodium falciparum Malaria. I. Antigenic Variation, Antigenic Diversity and the Role of the Spleen", J. Exp. Med., 157, 1137, (1983)). There is evidence that the weak and temporary immunity exhibited by malaria patients, formerly called "premunition", is due at least in part to these parasite-dependent erythrocitic antigens, which are also specific to the parasite strain in question (M. Hommel, "Antigenic Variation in Malaria parasites", supra). Diversity is an obvious obstacle in the quest for effective immunogenic methods for human vaccination.
Antigenic "variation" is a further difficulty which refers to the capacity of a single organism to express sequentially a variety of antigens of different specificities. Thus, the Plasmodium population parasitizing a given individual may "switch" the antigens it expresses. Variation has been very well studied in, among other species, experimental P. knowlesi malaria in monkeys. For example, two cloned variants were shown to cause the emergence of two red blood cell membrane proteins, each which differed immunologically and even in molecular size (R. J. Howard, J. W. Barnwell and V. Kao, "Antigenic Variation in Plasmodium Knowlesi Malaria: Identification of the Variant Antigen on Infected Erythrocytes", Proc. Natl. Acad. Sci., USA, 80, 4129, . (1983)).
In the context of these sources of antigenic differences between P. vivax isolates and their consequences with regard to vaccination, it is important that the merozoites of different strains of P. vivax share the same receptor for penetration into red blood cells, i.e., the Duffy molecule (Miller et al, N. Engl. J. Med., supra). In addition, regardless of its capacity to vary other antigenic molecules, the parasite recognition molecule, i.e., the molecule that binds to the Duffy molecule, must remain constant since it is the complementarity between it and the invariant receptor that allows the penetration of merozoites into erythrocytes and thus, the continuity of the infection. Changes in the ligand specificity of this molecule would result in the loss of the parasite's capacity to infect, since P. vivax merozoites appear to be unable to utilize other human red blood cell receptors for their penetration in vivo, as shown by the resistance of Duffy negative erythrocytes.
If antibodies against the parasite's ligand could be induced in susceptible individuals, such antibodies would recognize the ligand on the surface of the merozoites and would block its capacity to interact with red blood cells. They might also result in a reaction similar to that caused by antibodies to the so-called circunsporozoite (CS) protein, which terminates in the destruction of the sporozoites's viability in vitro as described by R. S. Nussenzweig and V. Nussenzweig, "Development of Sporozoite Vaccines", Philos. Trans. R. Soc. Lond (Biol), 307, 117 (1984) and D. R. Spriggs, "The Malaria Sporozoite Vaccine: Parasitology's Brave New World", J. Infect. Dis., 152, 655, (1985). It has not been possible, thus far, to identify, characterize and prepare such ligand molecules to allow a test of this hypothesis.
Blocking of P. vivax penetration by conventional antibodies of the Duffy blood group was described by H. C. Spencer, L. H. Miller, W. E. Collins et al, "The Duffy Blood Group and Resistance to Plasmodium Vivax in Honduras", Am. J. Trop. Med. Hyg., 27, 664, (1978).
It is, accordingly, an object of the present invention to provide an improved way of combating malaria resulting from P. vivax by blocking the erthrocytic receptor of this parasite with an epitopic-specific monoclonal antibody.
Another object of the present invention is to prepare vaccines for the immunization of individuals susceptible to the so-called Benign Tertian Malaria caused by P. vivax, a parasite whose port of entry into red blood cells is the molecule that carried the blood group antigens of the Duffy system, which is thus referred to as its receptor. Conversely, P. vivax depends on the expression on its surface of a specific molecule (referred to as the ligand), stereochemically complementary to the receptor for its binding to and/or, subsequent penetration into the erythrocyte. This ligand is thoroughly inhibited in its binding to the receptor (in the specific case of P. vivax, the receptor molecule corresponds to the Duffy blood group antigen) by the monoclonal antibody which is the subject of the present invention and which possesses the same sterochemical specificity. Thus, immunization with this monoclonal antibody as a vaccine will elicit an immune response to its combining site, termed an anti-idiotypic response, resulting in antibodies which will also recognize the immunologically identical epitope on the ligand and hence will protect the host against the erythrocytic forms (merozoites) of P. vivax.
The present invention concerns the use of monoclonal anti-receptor antibodies immunochemically specific for the epitope used by P. vivax and for those used by other parasitic organisms, including viruses and bacteria, to penetrate into host cells. These monoclonal antibodies are used according to the present invention, to generate or elicit the corresponding anti-idiotypic antibodies which by virtue of their specificity for the parasite's ligand molecule are useful in the serodiagnosis and treatment of established infection.
In accordance with another aspect of the invention, the antibodies according to the invention can be used to produce anti-idiotypic antibodies outside the human body and such anti-idiotypic antibodies can be used to isolate the particular molecules of P. vivax which are responsible for red blood cell penetration by P. vivax. Those molecules will combine with the anti-idiotypic antibodies, the complexes isolated and then broken apart to liberate the particular parasitic molecules. Those molecules can thereafter be used in various ways to generate an immunologically adequate vaccine that results in the production of antibodies to such particular molecules.
The present invention also concerns a general method for producing immunity against an infectious microorganism based on the stereochemical complementarity between the ligand molecule on the microorganism and its receptor in the host's cell. This complementarity is used according to the present invention to generate antibodies against the ligand by immunizing with monoclonal antibodies against the ligand-binding region of the receptor molecule. Such monoclonal anti-receptor antibodies, which react with the exact area of binding of the ligand molecule of the parasitic organism, bring about protective immunity because they elicit anti-idiotypic antibodies that react with the stereochemically equivalent region of the ligand.
Fundamental to the herein described invention is the fact that there is obtained a monoclonal antibody which identifies the human blood group antigen Fyab of the Duffy system. As concerns the present invention, more specifically, there is obtained a monoclonal antibody that blocks penetration of P. vivax malaria parasite into human red blood cells by virtue of effectively blocking the site on the Duffy-erythrocytic molecule used as a target by the P. vivax malaria parasite. There is provided according to the invention a monoclonal antibody the combining site of which has the same stereochemical configuration as the ligand site on the P. vivax malaria parasite. This antibody is prepared by standard methods. Specifically, red blood cells from a donor carrying the Duffy (ab) group are injected into an animal such as a mouse, the animal's spleen is excised and the spleen cells separated, fused with myeloma cells to produce a hybridoma and the hybridoma cloned in the wells of tissue-culture microtiter trays. The antibodies produced by the cells in various wells are tested with blood cells of the four different Duffy kinds. viz.,
Fy a+, b+, (ab)+
Fy a-, b+, (ab)+
Fy a+, b-, (ab)+
Fy a-, b-, (ab)-
Those which selectively react with all the first three, but not the fourth, are potentially useful in the practice of the invention. The selected cloned hybridomas produce as large quantities of suitable monoclonal antibodies as desired.
Stated otherwise, the present invention concerns a monoclonal antibody that can react with all human red blood cell samples that contain either or both blood group antigens Fya and Fyb and does not react with any other human blood samples. This specificity is similar to the well known blood group Fy3, but differs from it in that the Fy.sup.(ab) epitope is sensitive to degradation by proteolytic enzymes, such as trypsin, papain and ficin.
Such antibodies can be passively utilized for blocking a patient's red blood cells so that the penetration of P. vivax merozoites is efficiently impeded or can be used as antigens injected into mice to produce anti-antibodies, i.e., anti-idiotypic antibodies. Among such secondary antibodies, some will have binding sites immunologically complementary to and reactive against the ligand molecule of P. vivax and will therefore interfere with its penetration into the red blood cells. The anti-Fy.sup.(ab) monoclonal antibody used in susceptible humans will lead to the formation of similar human anti-idiotypic antibodies, which also recognize the red blood cell binding ligand on P. vivax merozoites, and which will provide protection against P. vivax penetration.
In other words, anti-Fy.sup.(ab) may be used as follows:
(a) as passive blockers of the receptors, "hiding" them from the parasite's ligand in order to prevent the parasite from penetrating into red blood cells, or
(b) to induce anti-idiotypic antibodies, either in susceptible humans (which renders anti-Fy.sup.(ab) a vaccine) or in an animal which would lead to the production of hyperimmune globulins against the parasite's invariant red blood cell binding site. Such foreign hyperimmune globulins may be used in passive immunotherapy, while anti-idiotypic antibodies induced in a susceptible host provide active immunity against the ligand.
In the present invention, the ligand molecule of P. vivax is by-passed for immunization purposes, by using instead antibody molecules possessing the identical specificity, i.e., which are immunochemically specific for the same epitope on the red cell receptor (Duffy) molecule. In the present invention, there is prepared such antibodies in the form of murine monoclonal antibodies having the capacity to inhibit the penetration of P. vivax into Duffy-positive red blood cells. This inhibition is similar in character and specificity, but stronger in quantitative terms, than that reported for conventional antibodies of the Duffy blood group specificity (H. L. Spencer et al, supra). In addition, these antibodies precipitate, from solubilized erythrocytic membranes, a 45kD glycoprotein bearing the ; Duffy blood groups.
The monoclonal antibodies of the present invention when injected into immunologically competent hosts result in the formation of anti-idiotypic antibodies, i.e., antibodies that recognize the specific combining site (idiotype) of the immunizing anti-Duffy monoclonal antibody. Given that the combining sites of both this anti-Duffy antibody and the ligand molecule of P. vivax recognize one and the same receptor epitope, antibodies reacting against the first should, by necessity, also recognize and react against the second.
Immunizations can be performed by injecting immunoglobulin molecules purified from the monoclonal antibody into host animals. The antibody response of the immune animals will contain anti-idiotypic antibodies which, according the present invention, will react not only with the anti-Duffy molecules, but also with the ligand molecule on the surface of the parasite. These anti-idiotypic antibodies would be protective, if their hosts were otherwise susceptible to P. vivax, by virtue of their ability to interact immunologically with the parasite. Thus, the monoclonal antibody against the receptor molecule for P. vivax could serve as an immunogenic vaccine for the protection of susceptible individuals. In addition, extraction of the ligand from merozoites by using anti-idiotypic antibodies will permit the preparation of further immunogens from the same ligand molecule, as well as a detailed understanding of the molecular events of merozoite penetration. Finally, by their specificity against the indispensible (and most likely invariant) ligand molecule, these antibodies would be effective regardless of the parasite's strain.
The present invention relates to a novel method of immunizing susceptible human individuals against P. vivax merozoites and is based on the development of a mouse monoclonal antibody recognizing the parasite-binding region of the Duffy molecule, which is the human receptor for P. vivax merozoites. Because of its blood group specificity, the corresponding epitope . has been designated Fy(ab).
Since the monoclonal anti-Fy.sup.(ab) antibody and the ligand structures on the parasite's red cell-binding molecule recognize the same epitope, antibodies specific for the combining site on the anti-Fy.sup.(ab) antibody (anti-idiotypic antibodies), can be elicited, which will react with the parasite's ligand. Susceptible individuals who make these anti-idiotypic antibodies will be protected against P. vivax merozoites because (a) they block the ability of the parasite to recognize the erythrocytic receptor and (b) they may induce the lysis or inactivation of the Plasmodium cell by fixing complement.
There are three procedures for immortalizing antibody-producing B-cells in current use. These are: (1) the conventional fusion to a selectable myeloma cell line, as originally described by Kohler and Milstein, Nature, 256, 495-497, (1975), (2) transformation and immortalization by Epstein-Barr virus (on human B cells) as reported first by M. Steinitz, G. Klein, S. Koskimies, and Makela, Nature, 269, 420-422, (1977) and, (3) a combination of both techniques. However, it may be anticipated that other, more effective techniques may be used to yield antibody-producing cell lines, including transfection with genetically engineered constructs including the rearranged immunoglobulin genes coupled with efficient promotors.
One method of preparing the hybridomas according to the present invention comprises the following steps:
(a) Immunizing mice with human red cells from a donor having the Duffy (ab) blood group antigen. While BALB/cJ mice are preferred, it is contemplated that other mouse or rat strains could be used.
(b) Removing the spleens and/or lymph-nodes from the immunized animals and making a spleen or lymph-node cell suspension in an appropriate medium.
(c) Fusing the suspended spleen or lymph-node cells with mouse or rat myeloma cells from suitable cell lines by the use of any appropriate fusion promotor. The usually preferred ratio is about four nucleated spleen cells to each myeloma cell. Several mouse and rat myeloma cell lines are known and available, generally from members of the academic community or various deposit banks, such as the Salk Institute Cell Distribution Center, La Jolla, CA. Most commonly used are the 8-azaguanine resistant cell lines, which lack the enzyme hypoxanthine-guanine phophoribosyl-transferase. It is also generally preferred that the myeloma cell line used be of the so-called "non-secreting" type, i.e., one that does not itself produce any antibody, although secreting types may be used. While the commonly used fusion promotor is polyethylene glycol having an average molecular weight from about 1000 to about 4000 (commercially available as PEG 1000 to PEG 4000, etc.), other fusion promoters known in the art may be employed, including other chemicals, viruses and physical agents, such as electric discharges through the suspension.
(d) Diluting the mixtures of unfused spleen or lymph-node cells, unfused myeloma cells and fused cells and culturing these mixtures in a selective medium, which will not support the unfused myeloma cells for a time sufficient to result in the death of the unfused cells (about 14-16 days). The medium is one which will not support the enzyme-deficient unfused myeloma cell line. Hence, these myeloma cells perish. The unfused spleen or lymph-node cells are non-malignant, and thus survive only through a finite number of generations. Thus, after a certain period of time (about 14 to 16 days) these unfused normal cells are essentially all dead. The fused, hybrid cells, on the other hand, continue to reproduce because they possess both the malignant quality of the myeloma parent and the ability to survive in the selective medium of the normal cell parent.
(e) Selecting by limiting dilution, i.e., one in which the volume of diluent is statistically calculated to isolate a certain number of cells (e.g., 0.3 to 1) in a given volume of suspension deposited in each separate container (e.g., each well of a microtiter plate), or by alternative methods, such as by culturing in soft agars, and cloning hybridomas that produce and secrete the desired antibody of the desired blood group specificity, i.e., reacting with all human cells but Fy.sup.(a-b-) ones.
Once the desired hybridoma has been selected and cloned, the resultant antibody may be produced in one of two ways. The purest monoclonal antibody is produced by in vitro culturing of the desired hybridoma in a suitable medium for a suitable length of time, followed by recovery of the desired antibody from the supernatant. The suitable medium and suitable length of culturing time are determined empirically. This in vitro technique produces monoclonal antibody, free from other antihuman immunoglobulin. There is a small amount of other immunoglobulin present since the medium contains xenogeneic serum (e.g., fetal calf serum). This type of gamma globulin, however, is no consequence since its immunoglobulins content is very low and its lack of binding to human cells is routinely established for each batch before using it for this purpose. This in vitro method yields a concentration of monoclonal antibody usually in the 5 to 20 μg/ml range, which may be insufficient for some purposes.
To produce a much greater concentration of slightly less pure monoclonal antibody, the desired hybridoma may be injected into mice or rats syngeneic or semi-syngeneic with the strain of the myeloma, to which the spleen or lymph-node donor also belongs. The hybridoma will cause formation of antibody-producing tumors, which will result in a high concentration of the desired antibody (about 5 to 20 mg/ml) in the bloodstream and peritoneal exudate (ascites) of the host animal. To increase the volume of ascites, the hosts are pretreated with intra-peritoneal injections of irritants (e.g., pristane, Freund's adjuvant, silica gel, etc.).
Although the monoclonal antibody concentration is higher in ascitic fluids, normal immunoglobulins from the host animal containing species antibody are also present there.
However, the monoclonal antibody in ascitic fluids is typically of high titer and contains an extremely high ratio of specific to non-specific immunoglobulin.
When used for vaccination, the novel immunoglobulins of the present invention can be administered, with adjuvants, if warranted, by any medically acceptable route including the following: oral, intravenous, rectal, subcutaneous, intradermal or intramuscular.
The monoclonal antibody according to the invention has the following characteristics and properties:
(1) The monoclonal antibody of the present invention can be used as the immunogenic agent in a vaccine and can be produced in virtually limitless quantity.
(2) The region of the antibody molecule that bears the immunogenic moiety (idiotype) is located in the variable region which may be further purified in order to avoid the undesired immunogenicity of the constant region of the molecule.
(3) If desired, the antigen combining region of the monoclonal antibody can be transferred to a carrier molecule devoid of additional immunogenic properties for human subjects. This may be done by a number of methods that are equivalent in this regard, such as, by chemically binding the Fab fragment of the antibody molecule to an Fc fragment derived from human immunoglobulin or by genetically engineering an appropriate hybrid molecule using the necessary portion of the rearranged immunoglobulin heavy and light chain genes from the monoclonal-producing hybridoma cell line into human immunoglobulin genes from which the equivalent regions have been excised. Alternatively, the idiotype-bearing portions of the protein (or the DNA fragments encoding them) may be attached to other immunogenic molecules or particles (or to their respective genetic determinants in the case of the DNA fragments encoding the idiotypes).
(4) The monoclonal antibody of the present invention can precipitate from red cells, and thus may be used to chemically isolate, the human receptor for P. vivax which will permit the precise characterization of the ligand region of the receptor molecule. In turn, the purified red blood cell receptor, or synthetic molecules fashioned after it, may be used for binding to and isolating the parasite's specific recognition molecule. The purified ligand molecules from the merozoite could then be characterized and used as "blue-prints" for the preparation of synthetic peptides with protective immunogenic properties
(5) The monoclonal antibody of the present invention can be used to prepare anti-idiotypic monoclonal antibodies in mice. Those anti-idiotypic antibodies that additionally react with the combining site of P. vivax merozoites can be used as affinity probes, to isolate the ligand as was described in (4) above for the receptor on red blood cells and with the same objectives.
(6) The monoclonal antibody of the present invention and the anti-idiotypic antibody of the present invention can be used in the immunodiagnosis of P. vivax infection. Thus, the presence of P. vivax antigen in serum or other fluid may be detected and its concentration measured by its interference with the binding of the monoclonal anti-Duffy to either the Duffy molecule or to its monoclonal anti-idiotypic antibody. Since the parasite's ligand and the anti-Duffy antibody will react with the same combining site both on the Duffy molecule and in the monoclonal anti-idiotypic immunoglobulin, a simple competition assay can be designed using either enzyme-linked or radiolabeled reagents, or other labeling reagents.
(7) The use of monoclonal antibodies to the receptor molecule to induce anti-idiotypic responses which protect against parasites can be extended to organisms other than P. vivax. For example, it is now believed that the receptor for P. falciparum merozoites is located in the glycophorin A and/or glycophorin B molecules (L. Perrin, A. Perez and C. Chizzolini, "Malaria: Immunity, Vaccination and Immunodiagnosis", Experientia, 40, 1343, (1984)). Several monoclonal antibodies have been developed that react with epitopes on these two molecules (M. Nichols, "Monoclonal Antibodies to Human Blood Groups. A Method and Its Application", PhD Thesis, Cornell University, (1985); M. Nichols, R. E. Rosenfield and P. Rubinstein, "Two Blood Group M Epitopes Disclosed by Monoclonal Antibodies", Vox. Sang., 49, 138, (1985)) and further monoclonals may be prepared with this purpose. Other pathogens which penetrate human cells through defined receptors are known, e.g., the HTLV-III/LAV and Epstein-Barr viruses and similar approaches to specific vaccine development are contemplated.
(8) The monoclonal anti-Duffy antibodies may be used directly in vivo to block the red cell receptors for the parasite. This might be useful in the management of patients with particularly severe attacks of P. vivax malaria, in whom the level of parasitemia may be very high. In the same type of patients, but not simultaneously, passively administered anti-idiotypic antibodies may be useful by directly binding to and destroying the parasites.
The present invention also provides a method for the detection of the presence of P. vivax infection in a patient. The method employs insolubilized monoclonal antibody which identifies the human blood group Fy.sup.(ab) of the Duffy system and labeled, e.g., radiolabeled or enzyme labeled, monoclonal anti-idiotypic antibody to the aforesaid monoclonal antibody. Soluble P. vivax in the test sample will interfere with the binding to the insolublized monoclonal antibody of the labeled monoclonal anti-idiotypic antibody and will thus decrease the amount of the detectable label, e.g., the radioactivity or the enzyme, bound by the insolublized antibody.
Non-limiting examples of supports for affinity-separation of antibodies, including monoclonals, include the following: activated sepharose, activated cellulose and activated sephadex. "Activated" refers to the creation, on the insoluble material, of reactive chemical groups that will form covalent linkages with the antibody molecules when incubated together under appropriate conditions. Typically, reactive groups are introduced into the insoluble substrate by the action of cyanogen bromide (CNBr) at high pH.
The invention will be further described with reference to the following non-limiting examples:
Using the method of G. Kohler and C. Milstein, Nature 256, 495-496, (1975), a BALB/c mouse was immunized with washed human red cells of the Fy.sup.(a+b+) type by six weekly intraperitoneal administration of 107 erythrocytes each. The spleen of the mouse was then removed and a cell suspension prepared in tissue culture medium (RPMI-1640 with additional glutamine, 5mM). The spleen cell suspension was mixed with a suspension of the mouse myeloma cell line P3/NSO-Ag4-l (NS-0) (obtained from the ATCC) which, being deficient in the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), will not grow in tissue culture media containing hypoxanthine, aminopterin and thymidine (HAT media).
The mixture contained four spleen cells to one myeloma cell. Fusion was promoted by the addition of polyethylene glycol (PEG) of an average molecular weight of 2000. After fusion, the cells were washed free of PEG, resuspended in HAT medium and allowed to grow to a density of 106 live cells per ml and aliquots of 0.1 ml added to the wells of a 24-well tray containing feeder cells (from BALB/c thymus).
Partial changes of culture medium were performed at 3, 5 and 7 days and the supernatants removed 14 days postfusion and tested for the presence of antibodies that bind to human red cells. Since the process was conducted in the presence of HAT, essentially non-fused myeloma cells were dead at this time, which prevented them from possibly overgrowing the fused (hybrid) ones.
The unfused spleen cells were also dead because of their very limited capacity to grow ex vivo in this tissue culture medium. The hybrid cells grew and multiplied because the normal spleen cells contributed the enzyme HGPRT and the myelomatous cells for the capacity for indefinite proliferation. The supernatants from the wells containing colonies of hybrid cells were assayed on a panel of cells including the major Duffy genotypes: Fy.sup.(a+b-), Fy.sup.(a-b+) and Fy.sup.(a-b-). One well was found to contain antibodies that bound to the first two types and not the third. The cellular contents of that well were then recovered and suspended to a concentration of 3 cells per ml.
Aliquots of 0.1 ml were then added to fresh wells, so that on the average only one of every three wells received a cell and, thus, the colonies that resulted from the growth of this very diluted suspension are likely to be true "clones", i.e., descendents from a single progenitor. When the colonies attained a size of 102 cells their supernatants were again screened for the presence of Duffy antibodies and the 10 most strongly positive ones allowed to expand to a number of 105 to 106. Dilution of these cell suspensions to a concentration of 3 cells/ml and plating volumes of 0.1 ml as before resulted in the growth of doubly-cloned hybrid, antibody- producing cell lines. One of these, designated K6F4, ATCC No. 9332, deposited on February 25, 1987 with the American Type Culture Collection, Rockville Maryland, was grown to a total cell number of 109, and aliquots of 107 cells were frozen in liquid nitrogen to ensure the continuity of this cell line.
The concentration of monoclonal antibody at the time of maturity of a culture flask is 20�5 μg/ml. The cloned hybridoma also grows in vivo in mice of the BALB/c strain or of its first generation (Fl) hybrids. This growth is in the form of malignant myelomatous tumors. When live hybridoma cells are injected up into susceptible animals, they secrete high concentrations of antibody into the peritoneal spaces. "Priming" the animals with irritants such as incomplete Freund's adjuvant or Pristane injected into the peritoneum, before grafting the hybridoms, results in the formation of large volumes of ascites containing antibody in concentrations higher than 5 mg/ml.
The K6/F4 monoclonal antibody from Example 1 was tested for reactivity on a large panel of otherwise unselected human red cells, and others that include rare blood-types, with particular emphasis on the different Duffy blood groups. These tests were performed with the antiglobulin technique using rabbit anti-mouse gamma-globulin antisera, previously adsorbed with washed human red cells to remove contaminating anti-human (species) antibodies.
The monoclonal antibody was also tested against a panel of red blood cells from individuals of several non-human primate species, in parallel with eluates of conventional human antibodies of known Duffy blood group specificity.
Highly selected red cells panels were prepared locally by choosing donors of informative blood types or obtained commercially. A local panel was first used to confirm the initial screening results that indicated the antibody to be non-reactive with Fy.sup.(a-b-) red blood cells. The regular local panel contained three Fy.sup.(a-b-) samples which differ extensively in their phenotypes from other blood groups. All three were negative, as were the Fy.sup.(a-b-) cells in three Accugenics panels, while all others were strongly reactive. "Rare" cells of the following types were positive: Ge(-); Vel(-1, -2); Jk.sup.(a-b-) ; Oh(Bombay); Lan(-) Tj(a-); Rh null, (two examples); U(-); Hy(-)/Joa (-0; Jra (-); Wrb (-); K-2 and Lu.sup.(a-b-) (many examples) including both dominant and recessive forms; Fyx/Fyx; and two examples of the very rare Fy.sup.(a-b-) phenotype from white donors.
In addition, several hundred unselected blood donor samples were tested. All of which were Fy.sup.(a-b-), but no others, were negative.
Thus, the serological specificity of K6/F4 is similar to that of the Fy3 antigen, which is present whenever either of the Fya or Fyb genes are expressed. It is different from Fy5, a similar specificity which is, however, also absent from Rh null cells. The K6/F4 monoclonal antibody reacts well with Rh null cells.
Interestingly, however, the antigenic epitope recognized by K6/F4 differs from that of conventional Fy3 in its susceptibility to enzyme treatment.
Human red blood cells of the four relevant phenotypes, Fy.sup.(a+b-), Fy.sup.(a-b+), Fy(a+b+) and Fy.sup.(a-b-) were treated under standard conditions (American Association of Blood Banks, Technical Manual, 9th Edition, 1985) with the enzymes Ficin, Papain, Bromelin, Pronase, Neuraminidase and Trypsin. Aliquots were then exposed to (human) anti-Fya, anti-Fyb, anti-Fy3 and K6/F4 supernatant. All these enzymes, with the exception of Neuraminidase, abolished the reactivity of the monoclonal reagent, while only Pronase destroyed that of the human anti-Fy3. As is already known, Neuraminidase did not affect either Fya or Fyb ; Trypsin destroyed Fyb, but not Fya ; Bromelin is similar to Trypsin and both Ficin and Papain destroyed both antigenic specificities.
Thus, the specificity recognized by K6/F4 is conveyed by an epitope distinct at the molecular level, although very closely associated with Fya, Fyb and Fy3. This epitope was designated Fy.sup.(ab).
The tests of Example 2b were conducted as a further check on the specificity of the monoclonal anti-Duffy. These tests were performed in parallel with the conventional human reagents, using eluates prepared from positive human cells in order to avoid the species antibodies contained in most human sera (M. Palatnik and A. W. Rowe, "Duffy and Duffy-Related Human Antigens in Primates", J. Human Evolution, 13, 173, (1984)).
The reactivity was as listed below:
__________________________________________________________________________ Monoclonal K6/F4 Fya Fyb Fy3__________________________________________________________________________Gorilla ( Gorilla gorilla) + - + (weak) +Chimpanzee (Pan troglodytes) ++++ - + +Gibbon (Hylobates agilis) + - + +Rhesus (Macaca Mulatta) - - - + (weak)Baboon (Papio sp) - - NT +Squirrel (Saimiri sciureus) ++++ - - NTCapuchin (Cebus apella) - - - NTDourocoli (Aotus trivirgatus) ++++ - - +__________________________________________________________________________ NT = not tested - = negative test + = positive (weak) test ++++ = positive (strong) test)
The above results are significant to the objectives of the present invention, because the reactivity with the monoclonal K6/F4 reagent closely correlates with the susceptibility of cells to the penetration of P. vivax merozoites, as described below:
The techniques used in Example 3 to ascertain penetration of P. vivax merozoite were adapted from those described in L. H. Miller, S. J. Mason, J. A. Dvorak, T. Shiroishi and M. H. McGinnis, "Erythrocyte Receptors for Malarial Merozoites and the Duffy Blood Group System", Human Blood Groups, 5th International Convocation on Immunology, Buffalo, NY, 1976, Basel Karger, pp. 394-400, 1977. Standard numbers of merozoites are incubated with standard numbers of erythrocytes. In parallel wells, red cells or primates of different species are exposed to P. vivax in the presence of either monoclonal anti-Fy.sup.(ab) antibodies or monoclonal anti-Rh29 or anti-Kl4 as controls. Anti-Rh29 and anti-Kl4 antibodies are reactive with essentially all human and most primate red blood cells, but their antigenic epitopes are unrelated to Duffy. A third well for each erythrocyte donor contains only tissue culture medium instead of monoclonal antibodies. The two latter, control, wells allow the determination of the proportion of red cells that are "normally" penetrated by the parasite under these conditions. Thus, comparison between this proportion and that in the well containing the K6/F4 monoclonal antibody permits estimation of its inhibitory effect
This inhibition is well over 90% for human red cells and somewhat lower for Aotus and Saimiri erythrocytes. The inhibitory effects are reproducible and roughly parallel the serological reactivity of the red blood cell-monoclonal K6/F4 antibody combinations, as described above, even in the cases of primates that are negative for the conventional Duffy antigens, Fya and Fyb (Saimiri and Dourocoli).
The anti-Fy6 monoclonal antibody was tested for its capacity to immunoprecipitate the 42-45kD glycoprotein from human red blood cells that is also the binding site for alloantibodies to the Duffy blood group (T. S. Hadley, et al supra Identification of an Erythrocyte Component Carrying the Duffy Blood Group Fya Antigen, Science, 223, 597-599 (1983)). In fact, red blood cell membrane proteins, separated by SDS-PAGE and blotted onto nitrocellulose filters were exposed to labeled monoclonal antibody molecules and a single band of the appropriate molecular size and overall chemical characteristics was obtained.
All antibody molecules are, at the same time, antigens since their ability to function as antibodies, i.e., to bind to antigen, depends on a special stereochemical configuration which is specific for each antibody and is called an "idiotype". A monoclonal antibody immunoglobulin is constituted of exactly identical molecules, each having the same specific combining site, which, being complementary to the respective antigen, becomes antigenic for the antibody-producing host and to other animals of the same strain. In other words, the idiotype of an antibody leads to the production of anti-idiotypic antibodies. This antigenic property can thus be used to elicit such anti-idiotypic antibodies by injecting naive hosts with purified monoclonal antibodies produced in animals of the same inbred strain.
This is accomplished by first purifying the original monoclonal antibody (designated Abl) by affinity chromatography, emulsifying it in complete Freund's adjuvant and injecting this emulsion into the peritoneum and under the skin in multiple sites of BALb/c mice. A second, identical injection is given two weeks later. Subsequent injections require the use of incomplete Freund's adjuvant Although the schedule of these injections and the quantities of immunoglobulin injected are empirical and different procedures have been reported to be successful, in this case two further injections in complete Freund's are given two weeks apart and following the initial two injections in complete Freund's adjuvant by two weeks. The recipient mice are rested for two months followed by two bi-weekly injections of F6/K4 (Abl). One week later, the spleens are removed and fused with NSO myeloma cells. Hybridomas are grown as described elsewhere in this application and screening is performed by competitive inhibition of Abl binding to human red cells of appropriate Duffy type (i.e., other than Fy.sup.(a-b-)). This inhibition test consists of adding the supernatants of hybridomas putatively producing anti-idiotypic antibodies (Ab2) to a dilution of F6/K4 and allowing the mixture to react with Fy(ab) cells. The presence of Ab2 inhibits that reaction. Confirmation of the specificity of presumptive anti-idiotypic antibody produced by the hybridomas is conducted by measuring its binding to red blood cells (there should be none) and the inhibition of monoclonal antibodies of the unrelated specificities: Rh29, K2, Kl4, M, N, B and Wrb (again there should be none). All these control tests being negative, the cells making the anti-anti-Fy.sup.(ab) antibody are cloned by limiting dilution.
These Ab2-producing clones (anti-anti-Fy.sup.(ab)) are then expanded and used to produce large amounts of supernatant and ascitic fluids. Ab2 binding to, and inhibition of the red cell penetration by, P. vivax merozoites in subsequent experiments demonstrates that the epitope recognized by the anti-Fy.sup.(ab) monoclonal antibody is indeed the site used by P. vivax since the parasite shares the binding structure of the monoclonal antibody.
It will be understood that the specification and example are illustrative, but not limitative of the present invention and that other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.
|Cited Patent
|Filing date
|Publication date
|Feb 12, 1981
|Aug 21, 1984
|New York University
|Malaria vaccine
|Feb 9, 1983
|Sep 1, 1983
|D'antonio, Lawrence, E.
|Method for the purification of parasite antigenic factors
|Aug 15, 1984
|Mar 14, 1985
|University Of Illinois
|Method and materials for development of immunological responses protective against malarial infection
|A. C. Allison, "Polymorphism and Natural Selection in Human Populations", Cold-Spring Harbor Sympos., Quant. Biol., 29, 137 (1964).
|A. C. Allison, Polymorphism and Natural Selection in Human Populations , Cold Spring Harbor Sympos., Quant. Biol., 29, 137 (1964).
|D. R. Spriggs, "The Malaria Sporozoite Vaccine", Parasitology's Brave New World, J. Infect. Dis., 152, 655 (1985).
|D. R. Spriggs, The Malaria Sporozoite Vaccine , Parasitology s Brave New World, J. Infect. Dis., 152, 655 (1985).
|Davies et al., Transfusion, 1979, vol. 9(5), p. 638.
|F. B. Livingston, "The Duffy Blood Groups, Vivax Malaria and Malaria Sections in Human Populations: Review", Human Biol., 56, 413 (1984).
|F. B. Livingston, The Duffy Blood Groups, Vivax Malaria and Malaria Sections in Human Populations: Review , Human Biol., 56, 413 (1984).
|F. Zavala, A. Masuda, P. M. Graves, V. Nussenzweig and R. Nussenzweig, "Ubiquitey of the Repetitive Epitope of the CS Protein in Different Isolates of Human Malaria Parasites", J. Immunol., 135, 2790 (1985).
|F. Zavala, A. Masuda, P. M. Graves, V. Nussenzweig and R. Nussenzweig, Ubiquitey of the Repetitive Epitope of the CS Protein in Different Isolates of Human Malaria Parasites , J. Immunol., 135, 2790 (1985).
|H. C. Spencer, L. H. Miller, W. E. Collins et al., "The Duffy Blood Group and Resistance to Plasmodium vivax in Honduras", Am. J. Trop. Med. Hyg., 27, 664 (1978).
|H. C. Spencer, L. H. Miller, W. E. Collins et al., The Duffy Blood Group and Resistance to Plasmodium vivax in Honduras , Am. J. Trop. Med. Hyg., 27, 664 (1978).
|Hadley et al., Science 223, 1984, pp. 597 599.
|Hadley et al., Science 223, 1984, pp. 597-599.
|Hollingdale et al., J. Immunol. 132, 1984, pp. 909 913.
|Hollingdale et al., J. Immunol. 132, 1984, pp. 909-913.
|L. H. Miller, H. J. Mason, D. F. Clyde and M. H. McGinnis, "The Resistance Factor to Plasmodium vivax in Blacks, The Duffy Blood Group Genotype (a-b-)", N. Engl. J. Med., 295, 302 (1976).
|L. H. Miller, H. J. Mason, D. F. Clyde and M. H. McGinnis, The Resistance Factor to Plasmodium vivax in Blacks, The Duffy Blood Group Genotype (a b ) , N. Engl. J. Med., 295, 302 (1976).
|M. Hommel, "Antigenic Variation in Malaria Parasites", Immunology Today, 6, 28 (1985).
|M. Hommel, Antigenic Variation in Malaria Parasites , Immunology Today, 6, 28 (1985).
|M. Hommel, P. H. David and L. D. Oligino, "Surface Alterations of Erythrocytes in Plasmodium falciparum Malaria. I. Antigenic Variation, Antigenic Diversity and the Role of the Spleen", J. Exp. Med., 157, 1137 (1983).
|M. Hommel, P. H. David and L. D. Oligino, Surface Alterations of Erythrocytes in Plasmodium falciparum Malaria. I. Antigenic Variation, Antigenic Diversity and the Role of the Spleen , J. Exp. Med., 157, 1137 (1983).
|M. J. Friedman, "Oxidant Damage Mediates Variant Red Cell Resistance to Malaria", Nature, 280, 245 (1979).
|M. J. Friedman, Oxidant Damage Mediates Variant Red Cell Resistance to Malaria , Nature, 280, 245 (1979).
|Miller et al., Science 234, 1986, pp. 1349 1356.
|Miller et al., Science 234, 1986, pp. 1349-1356.
|Moore et al., Nature 295, 1982, pp. 529 531.
|Moore et al., Nature 295, 1982, pp. 529-531.
|R. J. Howard, J. W. Barnwell and V. Kao, "Antigenic Variation in Plasmodium knowlesi Malaria: Identification of the Variant Antigen on Infected Erythrocytes", Proc. Natl. Acad. Sci., USA, 80, 4129 (1983).
|R. J. Howard, J. W. Barnwell and V. Kao, Antigenic Variation in Plasmodium knowlesi Malaria: Identification of the Variant Antigen on Infected Erythrocytes , Proc. Natl. Acad. Sci., USA, 80, 4129 (1983).
|R. S. Nussenzweig and V. Nussenzweig, "Development of Sporozoite Vaccines", Philos. Trans. R. Soc. Lond (Biol), 307, 117 (1984).
|R. S. Nussenzweig and V. Nussenzweig, Development of Sporozoite Vaccines , Philos. Trans. R. Soc. Lond (Biol), 307, 117 (1984).
|Seuier et al., Clin. Chemistry 27(11), 1981, pp. 1797 1806.
|Seuier et al., Clin. Chemistry 27(11), 1981, pp. 1797-1806.
|Tharavanig, Southeast Asian J. Trop. Med. Pub. Health, 16, 1985, pp. 314 331.
|Tharavanig, Southeast Asian J. Trop. Med. Pub. Health, 16, 1985, pp. 314-331.
|Vernes et al., Am. J. Trop. Med. Hyg., 33(2), 1984, pp. 197 203.
|Vernes et al., Am. J. Trop. Med. Hyg., 33(2), 1984, pp. 197-203.
|Citing Patent
|Filing date
|Publication date
|Dec 4, 1990
|Oct 5, 1993
|Aktiebolaget Astra
|Nucleic acid probes specific for Plasmodium vivax and methods of using the same
|Jul 21, 1992
|Jul 30, 1996
|The United States Of America As Represented By The Secretary Of Health And Human Services
|Plasmodium vivax and Plasmodium knowlesi Duffy receptor
|Nov 15, 1996
|Jun 15, 1999
|New York Blood Center, Inc.
|Malarial binding site in duffy blood group protein
|Nov 15, 1996
|Apr 25, 2000
|New York Blood Center, Inc.
|Method of making monoclonal antibodies using polymorphic transgenic animals
|Jan 2, 1992
|Aug 27, 2002
|Immunomedics, Inc.
|Vaccines against cancer and infectious diseases
|Nov 9, 2001
|Jun 7, 2005
|University Of Vermont And State Agricultural College
|Toxoplasma gondii apical membrane antigen-1
|Oct 20, 1994
|Aug 7, 1996
|New York Blood Center, Inc.
|The cloning of duffy blood group antigen
|Nov 14, 1997
|May 22, 1998
|The New York Blood Center, Inc.
|Malarial binding site on duffy blood group protein
|Nov 14, 1997
|May 22, 1998
|The New York Blood Center, Inc.
|Method of making monoclonal antibodies using polymorphic transgenic animals
|U.S. Classification
|530/388.22, 424/153.1, 424/143.1, 435/334, 530/387.2, 435/343, 530/808, 424/151.1, 530/388.7, 435/70.2, 435/70.21, 424/131.1, 530/809
|International Classification
|Cooperative Classification
|European Classification
|May 18, 1987
Owner name: NEW YORK BLOOD CENTER, INC., 310 EAST 67 STREET NE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:RUBINSTEIN, PABLO;NICHOLS, MARGARET;REEL/FRAME:004711/0480
Effective date: 19870511
|Nov 2, 1993
|Certificate of correction
|Sep 5, 1995
|Fee payment
Year of fee payment: 4
|Aug 6, 1999
|Fee payment
Year of fee payment: 8
|Sep 12, 2003
|Fee payment
Year of fee payment: 12


text:
|See realtime coverage
As everybody else was talking about the much anticipated decisions of the Hillsborough jury, Michael Owen instead used his Twitter account to make infantile 'jokes' about babies crying and people breaking wind on the plane he was travelling on.
|See realtime coverage
Former Liverpool star Michael Owen believes Daniel Sturridge will be hurt by Jurgen Klopp's decision to leave him on the bench during the Reds' UEFA Europa League semi-final first leg with Villarreal on Thursday.
|See realtime coverage
Michael Owen has been criticised for posting on Twitter about his flight just after the jury's verdict in the Hillsborough inquest.
Pochettino's commitment is a major boost for Tottenham, and Owen has praised the Lilywhites for tying down their in-demand manager.
Michael Owen is tipping Manchester United to seal a 2-1 win over Leicester City in the Premier League clash at Old Trafford on Sunday afternoon.
Michael Owen is confident that Arsenal will ease to a comfortable victory over Norwich City in the Premier League on Saturday evening.
|See realtime coverage
Michael Owen has been named Liverpool's first official international ambassador. The role will see the BT Sport pundit engaging with fans around the world, as well as representing the club at various fan and commercial events.
Gary Lineker says Michael Owen is 'very good' at football commentary: 'It's the toughest of all gigs'
Most weekends at around 4pm, you're bound to notice Michael Owen trending on Twitter. It's not because he's announced a sensational return to playing football.
Michael Owen expressed his disbelief that Liverpool managed to lose at Estadio El Madrigal after Adrien Lopez's added-time winner sealed a 1-0 first-leg victory for Villarreal.
|See realtime coverage
Owen, who grew up supporting rivals Everton, enjoyed a good career at Anfield having come up through the ranks and spent eight years in the first team.
Former football pro Michael Owen is betting on two teams to dominate Euro 2016—German and France. "[The] world champions at the moment, which is Germany, they're really strong.
MICHAEL OWEN will make you NEVER want to go anywhere near Dubai in this excruciating advert. The former Liverpool and Manchester United striker becomes a helicopter pilot on a magical virtual-reality tour of the megabucks Gulf city.
The former Liverpool, Real Madrid, Manchester United and England striker chooses his six most significant matches... May 6, 1997: Wimbledon 2-1 Liverpool.
|See realtime coverage
However, Michael Owen has seemingly only tunnel vision when it comes to his former clubs, predicting that Liverpool will win with Newcastle failing to score.
Done Deal: Ex-Liverpool star completes return to Anfield. MICHAEL OWEN has returned to Liverpool. By Rhys Turrell / Published 21st April 2016.
Michael Owen. Topics. Games That Changed My Life, Michael Owen, Liverpool, Real Madrid, Manchester United, England. comments.
|See realtime coverage
Michael Owen is expecting Everton to put up a fight and hold Manchester United to a 1-1 draw in 90 minutes in Saturday's FA Cup semi-final clash at Wembley.
|See realtime coverage
Given that the two sides are currently the top two in the Premier League it is unsurprising that they make up nine of the eleven positions in the team.
|See realtime coverage
And Owen told Bet Victor: "Sunderland, much like their North-East rivals, are still heavily involved in the relegation battle at the foot of the table but gave themselves a massive chance of staying up with last weekend's 3-0 defeat of Norwich at ...
|See realtime coverage
Michael Owen has been looking forward to the Newcastle match with Manchester City. Tuesday night sees the two clubs meeting at St James Park withe Newcastle battling for survival and Manchester City looking to ensure Champions League qualification.

subset: commoncrawl


text:
You are not logged in.
One side effect of the newspaper business's decline is an editor shortage, Alison MacAdam writes. Whereas daily journalism once served as a training ground for young editors, today's fast-paced digital version devalues editing, and that's a shame: "Editing may not be sexy. It may not nourish the ego. But (do I need to say it?) great editing makes every story more distinctive and memorable. Editors give stories structure, they elevate characters and they hone focus."
Wisconsin reporter Bill Lueders was talking to high school students about the joys of journalism. Afterward, one student came to him with a question: "She was considering going into journalism and wondered if I had any advice. I told her something about getting real-world experience by writing for student papers, but perhaps I should have given a different answer: 'Don't.'" Also, Benjamin Mullin profiles some journalists who decided to go solo.
Recent longform failures — from sources like Rolling Stone and SBNation — show what can happen when writers and editors see only what they want to see, Michael Fitzgerald writes: "Sometimes we want to believe our own stories badly enough that we make them true, regardless of the evidence in front of us. That's what seems to have happened at SBNation when it published, then pulled, a story about Daniel Holtzclaw, the failed football player turned serial rapist."
Waves of layoffs and buyouts have swept through journalism generally and newspapers in particular over the past decade. Dale Maharidge tells some of the victims' stories and mourns the loss: "Like the story of Willy Loman, cast aside in his creeping middle age, the tale of today's discarded journalists is, at its core, a parable of the way our economy, our whole American way of being, sucks people dry and throws them away as their cultural and economic currency wanes."
Wade Roush interviews Jenna Pirog, producer of the New York Times virtual reality film "The Displaced," about the mechanics of doing VR and how to know when you have the right story to use it: "I think there are certain stories that lend themselves better to VR," Pirog says. "Any place that you wish you could transport your reader to, any situation that you wish they could understand on a visceral level, those are the ones that are grabbing me the most for VR."
Sam Roe writes about a recent Chicago Tribune investigation that brought data scientists, pharmacologists, and cellular researchers together with journalists to identify four drug combinations associated with a potentially fatal heart condition: "The Tribune didn't just report on what scientists were doing," Roe writes. "We came to them with an ambitious idea, connected them to other top researchers and then became an important part of the scientific effort."
Journalism projects drew more than $1.74 million on Kickstarter in the first nine months of 2015, and about $6.3 million between 2009 and 2015, for a total of 658 fully funded projects, a new Pew report says. Laura Hazard Owen writes that "the bulk of the funded projects (71 percent) are still coming from 'individuals not tied to any journalistic organization,' either alone or in small groups, Pew found." More from Benjamin Mullin.
As media outlets assert control over their employees' online activities, Denise-Marie Ordway writes about an academic report on journalists who struggle to control their personal brands while cashing a paycheck: "Often, reporters, editors and columnists maintain two or more accounts on each social media platform in an effort to keep their professional lives separate from their personal ones … Journalists face choosing between their jobs and personal online identities."
It's become a commonplace of print news — the thick envelope from Human Resources containing the latest buyout offer. Former USA Today reporter Bruce Horovitz writes about his buyout and life on the other side: "What happened to me and more than 80 USA Today colleagues could be sprung on you. So it's your brain — not your gut — that needs to pay attention. Way before the 'voluntary retirement' message hits your inbox, there are steps you need to take to be ready."
Shan Wang discusses a new Tow Center report on the strengths and weaknesses of automated journalism — computer programs that write stories for outlets such as the Associated Press: "It won't work in domains where no structured data is available or the data available is fuzzy, and it can't provide the why of a story, only the what. But its potential in increasing speed, scale, and accuracy is great — algorithms 'do not get tired or distracted.'"


text:
MANIAC. MANIAC COP. VIGILANTE. There are few directors that have brought action and horror to the streets of New York City better than William Lustig. A master of horror in his own right, Lustig's twisted sensibilities have led to some of the most fun cinematic offerings of the past thirty years, and that's before considering his excellent second career with the DVD/Blu-ray distributor Blue Underground. Now, Lustig becomes a maniac when he joins this week's episode of MONSTER PARTY!Read more »
Fearful Features,Features/Interviews,Home,News Fangoria Staff
FANGORIA Podcast Network: "THE HORROR SHOW" says Goodnight to "SEE NO EVIL"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
For longtime fans of sports entertainment, the bleedover between WWE and the horror genre is quite noticeable. Whether you've got The Undertaker, The Wyatt Family or any of the other myriad creepy wrestlers from throughout WWE history, there's always been room for things to get darker and more wicked in professional wrestling, which certain translated into WWE Films' horror output. And for this week's installment of THE HORROR SHOW, Sean & Joe square off in a handicap match against WWE Films' first genre endeavor, SEE NO EVIL!Read more »
FANGORIA Podcast Network: "THE RANTS MACABRE" Buzzes Around "THE FLY"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
The remake discussion is one that is all-too-familiar to horror fans everywhere, with some of the most heated debates out there covering the updates, reboots and shot-for-shot remakes that come from the studio system. However, many forget that remakes do pose the opportunity for petrifying properties to go in new, disturbing directions, whether it's THE THING, MANIAC or THE FLY. And with that in mind, this week's Lunch Hour Review episode of THE RANTS MACABRE turns a microscope on both versions of THE FLY!Read more »
FANGORIA Podcast Network: Joe & Pat crawl through "Sloth" on "WE'LL SEE YOU IN HELL"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
Folks, face it: we're all guilty of the sin of "Sloth." Sure, we put in effort when we the cards are on the table, but with the stress of everyday life and general anxiety, cutting corners and taking breaks are as regular as sleeping and breathing in our regular routine. And so it's no surprise that Joe and Pat will be taking on "Sloth" on this week's WE'LL SEE YOU IN HELL!Read more »
"HOLIDAYS" (Movie Review)Home,Movies/TV,News,Reviews Michael Gingold
HOLIDAYS is worth celebrating. Tackling such a perfect subject for an anthology horror film that it's a surprise no one's done it before, it offers an overall satisfying assortment of approaches to perverting those special times of year.Read more »
FANGORIA Podcast Network: "THE GIRLS IN THE BACK ROW" Revive "CARRIE"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
Last week, THE GIRLS IN THE BACK ROW kicked off their fourth month of 2016 with Fred Dekker's NIGHT OF THE CREEPS, a bona fide cult classic that also ushered in TGITBR's macabre new artwork. Yet for the second installment of their "Dance Until You Die" series, Kate & Tab switch gears to ask the very first Stephen King feature film adaptation to the prom. That's right: with Kate previously having never seen this classic chiller, THE GIRLS IN THE BACK ROW are going to delve into Brian de Palma's seminal '70s scare flick, CARRIE!Read more »
Q&A: Filmmakers Kevin and Matthew McManus on the Voyeuristic Creepfest "13 CAMERAS"Fearful Features,Home,Movies/TV,News Michael Gingold
The invasion of one's home is one of the most frightening concepts in horror, and it's even scarier when the villain doesn't have to break in. That's the idea behind 13 CAMERAS, opening tomorrow; FANGORIA got exclusive words with producers Kevin and Matthew McManus.Read more »
Sci-Fi Horror "THE CURSE OF SLEEPING BEAUTY" Gets Free NYC screening on May 9th!Home,Movies/TV,News Fangoria Staff
You've never seen a fairy tale like this when FANGORIA hosts a free NYC screening of THE CURSE OF SLEEPING BEAUTY, director Pearry (NECROMENTIA) Teo's new horror fantasy. The screening will be held on Monday, May 9th at 7 p.m. at the Helen Mills Theater (137-139 West 26th Street). Set in present day, the movie stars Ethan (NOTHING LEFT TO FEAR) Peck, Natalie (TRUE BLOOD) Hall, India (UNDERWORLD: AWAKENING) Eisley and original WILLARD lead Bruce Davison. Rising indie horror sensation Teo, who also helmed DRACULA: THE DARK PRINCE, THE GENE GENERATION and THE EVIL INSIDE, will attend the show and take part in a Q&A.Read more »
FANGORIA Podcast Network: "THE HORROR SHOW" Falls For "THE LOVED ONES"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
For their second episode of April, THE HORROR SHOW moves on from creature features with miniscule monsters to a whole different breed to psychopath! So Sean & Joe are going Down Under for a story of obsession, guilt and unrequited love when they party with Sean Byrne's THE LOVED ONES!Read more »
FANGORIA Podcast Network: "THE RANTS MACABRE" Scoops Out "ICE CREAM MAN"!Books/Art/Culture,Features/Interviews,Home,News Fangoria Staff
We've all been there: a good friend recommends a fright film, you check it out and- simply put- you question their taste in terror titles. Hell, half of the appeal of checking out the obscure and odd films from throughout horror history is the chance that you'll either find a bizarre genre gem or something simply unbearable. And with that in mind, this week's Lunch Hour Review episode of THE RANTS MACABRE finds Darren & Mindy searching for common ground on 1995's ICE CREAM MAN!Read more »
Q&A: Star/Scripter Kate Siegel Speaks Up About "HUSH"Fearful Features,Home,Movies/TV,News Michael Gingold
When the blood-chilling, pulse-quickening survival-horror film HUSH premiered globally on Netflix over the weekend, audiences were introduced to a powerful new horror heroine. FANGORIA spoke exclusively to the woman behind the role as both actress and co-scripter, Kate Siegel.Read more »
FANGORIA Podcast Network: "SPLAT CHAT" Collects "THE HOARDER" Director Matt Winn!Books/Art/Culture,Features/Interviews,Home,News Steve CraigAs I move forward in pre-production of my feature debut, I can't help but share the details of my journey. It is quite possibly the most thrilling experience of my life thus far, to secure a cast and crew with excitement for the project, and tremendous initiative. In this episode, I begin with a cast announcement, as well as explaining my ideals of an enthusiastic cast and crew.Read more »


text:
Hospital hosts birthday party for Bengali girlThiruvananthapuram: KIMS hospital here turned a birthday party venue on Thursday, where the first birthday of Adrin Dhara from West Bengal was celebrated. Adrin Dhara had undergone a liver transplant surgery at the hospital 45 days ago and is ... Times of India, 1 month ago
The Story of India's First Dancing Girl
BENGALURU: For nearly a decade after he first encountered India's Gramophone Woman, Gauhar Jaan, writer Vikram Sampath yearned to see her in motion. The dream finally came true when Lillete Dubey's production Gauhar, adapted for the stage by ...New Indian Express, 1 month ago
The inside story: How a Bengal girl got NASA internship and Oxford scholarship
Sataparna Mukherjee is appearing for her Class 12 exams, but instead of being immersed in studies, all that this 18-year-old from Madhyamgram in West Bengal has been doing over the last week is answering scores of calls from reporters and smiling ...Yahoo! India, 1 month ago
Cop faces stern action for misnaming girl
The West Bengal Commission for Women is seeking punishment for a police officer for causing "great offence" to a 15-year-old girl and her family by misnaming her as "Dharshita" (Bengali for a rape victim) in their records. Atanu Panihrahi, a ...The Echo Of India, 1 month ago Kolkata policeman misnames girl, faces stern action Prokerala, 1 month ago KILLING IN POLICE CUSTODY: Trial begins against 3 police officers New Age Bangladesh, 1 week ago
#MarryMeA... love in the time of Twitter
What did a good Bengali boy do when he liked a girl? Told Ma, of course. Today, he tells the world to tweet his proposal to the girl! That's what best-selling romance writer Durjoy Datta did to get a "Yes" out of his girlfriend on Tuesday, sparking a social ...The Telegraph, 2 months ago
Rutgers Girl Shabnam Abedi's Album Scores In Bangladesh And India
By Fredda Sacharow Shabnam Abedi says the melodies of Bengali composer Kazi Nazrul Islam, a poet-philosopher born in the late 19th century, have been hardwired into her soul music she grew up with as the New Jersey-raised child of emigres ...News India Times, 2 weeks ago
Bdesh cricketer Hossain apologises for misdeed
Dhaka, April 28 A Bangladeshi Test cricketer banned from the game after he was charged with torturing an 11-year-old girl he employed as a maid apologised on Thursday and appealed to be allowed to return to the game. Shahadat Hossain, who has ...Himalayan Times, 6 hours ago Bangladesh pacer Shahadat says sorry, eyes return The Gulf Today, 10 hours ago Disgraced Bangladesh Cricketer Shahadat Seeks Comeback IBNLive, 17 hours ago Disgraced Bangladesh cricketer seeks comeback The Express Tribune, 18 hours ago
Dad Missive Blows Up in TMC's Face
KOLKATA: Even as the father of Sayantika, the three-year-old girl beaten up by Trinamool Congress workers on Monday, stated allegedly under duress that the incident had nothing to do with elections, local party MP Dinesh Trivedi condemned the ...New Indian Express, 9 hours ago
Shahadat apologises to Bangladesh for torturing under-age girl; wants to return to cricket
Dhaka :Bangladeshi Test cricketer Shahadat Hossain, who was bannedfrom the game after he was charged with torturing an11-year-old girl he employed as a maid, apologised on Thursday andappealed to be allowed to return to the game. Shahadat ...Firstpost.com, 17 hours ago
Gujarat: 7-month-old baby girl dies after falling into borewell
news Nation State World South Asia Sci Tech Pics Exclusive Blogs Archives entertainment Red Hot Reviews Movies Glam Talk Bookworm TV Celebrity Romance Pics Videos And More Exclusive Blogs sports Cricket Football ...ZeeNews.com, 1 day ago Kashmir firing: Not molested by Army soldier, clarifies girl ZeeNews.com, 2 weeks ago Meet nine-year-old girl 'Muskan' who runs a library for slum kids in Bhopal ZeeNews.com, 1 month ago Delhi: Girl gangraped in a moving car, one accused arrested ZeeNews.com, 2 months ago
Realtime News
on your WebpageAdd Widget >Get your members hooked!


text:
Hearing the noun ice used outside of the frozen-water context has got me thinking about the lyrics of "Thrift Shop", a song by the hip-hop duo Macklemore & Ryan Lewis. Check it out: I'm just pumped, I bought some sh*t from a thrift shop. Ice on the fringe, it's so damn frosty, the people like, "Damn, that's a cold-ass […]
Word of the Day: tmesis - the separation of parts of a compound word…... ow.ly/8K9pTQ
How long do slang words last for? We explore the lifespan of slang… oxford.ly/KCDXuE pic.twitter.com/hikk2cxTmU
Guest blogger David Norman takes us through the naming of dinosaurs: oxford.ly/19l0Oml pic.twitter.com/Y4LjeB9Xd3
On #CincoDeMayo, a look at Tex-Mex language in English: oxford.ly/1c0sm7p pic.twitter.com/zwy76zgPgm
'Dumpster fire' has recently been added to OxfordDictionaries.com. Find out what it means: oxford.ly/1VL3FAw pic.twitter.com/jmGqGW5WwW


text:
Ashish spent eleven
years in the engineering group at Yahoo! as one of the first one hundred
employees of the company. Culminating in leading engineering for the
Yahoo! Commerce Division, Ashish has extensive experience
conceptualizing and leading the development of commerce-oriented
consumer internet technologies. Like Jasper, Ashish has a long-standing
passion for both offers and social-oriented products – and championed
products such as Yahoo! Trip planner.
Neil deGrasse Tyson and Al Gore on the future of our planet — and everything else
More "Innovators" »
My husband and I are business partners who just had our first child — here's how we make it work
More "What Matters" »


text:
- Entertainment
LATE NIGHT ROUNDUP: Eddie Murphy Welcomes 9th Child, Miles Teller Boxing Film Out In November, & More!
- Music
- Style
Trending right now
- Beyonce Ditches Latex Gown To Hit Up Met Gala After Party With Solange
- Beauty Is Pain? Kylie Jenner's Met Gala Dress Actually Made Her Bleed
- Met Gala 2016: Beyonce, Zendaya Lead Our Picks For Best Dressed
- Basically Every Nude Celebrity Photo Shoot There Ever Was (NSFW PHOTOS)
- Michelle Obama Out-Dressed A Host Of Celebrities At Her Final White House Correspondents' Dinner
- 10 Ways To Join The Illuminati (PHOTOS)
- News
Trending right now
- SMH! 23-Year-Old Woman Possibly Pregnant By 13-Year-Old After Posing As Teenage Girl Online (VIDEO)
- Big Meech Looks To Land Presidential Pardon, Pens Six-Page Jailhouse Letter To Russell Simmons For "Relief From Draconian Plea Deal"
- 10-Year-Old Girl Raped By Younger Classmate As "His Sister Held Her Down" In Elementary School (DETAILS)
- HORRIFIC! Footage Shows Two Girls Brutally Beating 16-Year-Old Before Holding Her Down To Be Raped (GRAPHIC)
- Afeni Shakur, Mother Of Tupac, Dead At 69
- Congratulations Black America, We've Made The KKK Very Proud!
- Quizzes
- Video
Extra Butter: Chadwick Boseman & Chris Evans Talk Rolling Out The Black Panther In "Captain America: Civil War"
Passenger Claims Will Smith Shooter Saved His LifeStaff Writer
Friends In Need: Kim Kardashian Visits Will Smith's Wife After His Tragic DeathBruce Goodwin II , Associate Editor
New Video In Will Smith Shooting Raises QuestionsStaff Writer
10 Couples From The '90s Still Together TodayKiyonna Anthony , Editor
You May Also Like
Beyonce Stars With Blue Ivy In Commercial For Ivy Park Clothing Line & Poses For Two Covers Of ELLE MagazineCloseSign up for our newsletter and never miss the hot storiesThank you for subscribing to Global Grind! Please be sure to open your today's newsletter so we're added to your Safe Senders list.
- Music


text:
Cart Checkout 0
Your Help is Here! 800.743.3206
VIP Membership Terms: Normally $24.99 per year, but your Web Exclusive deal means you enjoy 3 months of VIP Family Benefits for $1.99. Check out your savings and benefits below.
Cancellation: Rest assured you can cancel your new membership at any time during the year at a pro-rated rate, simply call your VIP Hotline at 800.543.7309 or click here to submit your cancellation request. Benefits and prices are subject to change.
Want more info? Click here and read 'til your heart's content or call your VIP Hotline at 800.543.7309
Trail Mix Plus Insulated 2 Bottle Belt 20 ounce
Trail Mix 2 Bottle Belt
Sport Wash 20 ounce
Hydro Flask
20 ounce Wide Mouth with Flip Cap
Hydraform Jett-Lite Thermal 20 ounce
Mercury 2 Bottle Belt 20 ounce
Water Bottle 20 ounce
Firecatcher 20 ounce Vest
20 oz. Replacement Bottle
Trail Mix Plus 2 Bottle Belt (20 ounce)
Back to top
ENJOY YOUR BIGGEST BENEFITS EVERY DAY Get FREE Shipping every day • Your WARP SPEED PROMISE • 90-Day Ultimate Test Run On Shoes • Tons More Perks! JOIN NOW!! �
Become a Fan & Follow Us.


text:
Los Angeles - Actor Mel Gibson and his ex-girlfriend, Oksana Gigorieva, have reached a settlement of their bitterly fought separation.
Los Angeles Superior Court officials said in a statement late on Friday that the resolution came at the end of a multi-day settlement conference. Terms and conditions of the settlement were not announced and the court said that a hearing is set for Wednesday.
It said the civil financial agreement would be heard in open court but one of the most contentious issues, custody of the couple's small daughter, will be discussed in closed session.
The agreement appeared to conclude a legal saga which burst into headlines last year when Gigorieva, a Russian musician, reported Gibson had hit her during a fight at his Malibu home in January 2010.
24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.
She may be too young to appreciate it, but Princess Charlotte has received an extraordinary array of birthday gifts. Read More »
Several news organisations are reporting that prescription drugs were found with Prince when he was found dead in his Paisley Park complex. Read More »
Cape Town show pics.
New single.
All the deets.
Show review.
Live gig pics.
South AfricaCity Press
Cape TownCity Press
MpumalangaCity Press
HousesR 3 000 000
TownhousesR 1 579 000
HousesR 5 395 000


text:
The Science Insider
Jason Lindsey is an award winning Outreach Science Educator for Hooked on Science. Each year Lindsey performs science experiments at more than a hundred schools and community events. Lindsey's science segment "Hooked on Science" airs on television stations across America and has earned awards for outstanding science coverage.
Fire Tornado
Posted Friday, May 20, 2011, at 7:41 AM
WPSD Local 6 Meteorologist John Champion and I create a fire tornado. Go to www.hookedonscience.org for experiments that might get you and your family "Hooked on Science."
Join me and make the switch to WPSD Local 6 in May. You can watch the Hooked on Science semgent ONLY on WPSD Local 6 each Saturday between 8 a.m. and 9 a.m.
Respond to this blog
Posting a comment requires free registration:
- If you already have an account, follow this link to login
- Otherwise, follow this link to register


text:
Xbox 360 Games
This page contains NFL Blitz Hints for Xbox 360 called "Easy Safety Dance Achievement" and has been posted or updated on Jan 5, 2013 by blazeboy112.
Boxshot & Details
- Developer: Ea Tiburon
- Publisher: Electronic Arts
- Genre: Sports
- Release: Jan 4, 2012
- ESRB: Everyone 10+
Easy Safety Dance Achievement
Report Problem
Please submit a problem for any incomplete, non-working or fake cheat listed above.
More Hints
From: imjames407
From: Carlo497
From: blazeboy112
From: Casemiister
From: terry taliban
From: gilligan1987
Back to all Cheats
From: wadebarnes
Stuck in this game? Set a specific, clearly defined question and let other gamers answer your question or view answers to previously asked questions. If you think you are an expert then please try to help others with their questions.
Ask a Question
Videos You May Like...
Guilty Gear 2: Overture - Gameplay Video
- Apr 10, 2016, Views: 14
The Witness - Gameplay Video
- Mar 18, 2016, Views: 42
The Walking Dead: Michonne - A Telltale Miniseries: Extended Preview Trailer
- Feb 23, 2016, Views: 56
Space Assault Dragstar - Gameplay Video
- Jan 13, 2016, Views: 116
More Options
New Released Games
- Archer Karate Warrior PRO, (iOS)
- Amazing War Helicopter - Flaying Strike Race Skills, (iOS)
- Advance Formula Racing Pro, (iOS)
- Mystery Of Farm House, (iOS)
- Magical Street Free Hidden Object, (iOS)
- Quiz Books Question Puzzles Games Free - "Spider Man Edition", (iOS)
- Crazy Fruit Mania, (iOS)
- Wild Forest Hunt, (iOS)
- Bottle Shoot With Stone - 3D Bottles Shootout Training With Rocks And Stones, (iOS)
Top Featured Games
- Starlight Drifter, (PC)
- Uncharted 4: A Thief's End, (PS4)
- Downtown Nekketsu Monogatari SP, (3DS)
- LEGO Star Wars: The Force Awakens, (PS4)
- Deus Ex: Mankind Divided, (PS4)
- Forestry 2017 - The Simulation, (XONE)
- Skylanders Battlecast Cards To Life, (AND)
- Mafia 3, (PS4)
- Paragon, (PS4)
Games You May Like


text:
- Real talk: Allen West will not be bullied, thank you very much (Hot Air)
- The Supreme Court Stakes in 2012 (Wall Street Journal)
- Someone Thought This Was a Good Idea (Roll Call)
- HHS inspector general: Health grants could have illegally funded lobbying (The Hill)
- Supreme Court's Obamacare Decision Is By No Means The Final Word (Forbes)
- Hospitals 'letting patients die to save money' (UK Telegraph)
- Eleven hospital staff suspended after man dies on hospital doorstep (UK Telegraph)
- Surgeon did not read notes of man who died of thirst (UK Telegraph)
- IRS Gearing Up to Enforce Obamacare Tax (Heritage Foundation)
- Reid's Unconstitutional Gambit on Small Business Taxes (Heritage Foundation)
- Obama To Sign Anti-Second Amendment U.N. Gun Treaty (Investor's Business Daily)
- Off the Rails (City Journal)
- 2 MS-13 gang members arrested in Salisbury (Charlotte Observer)
- Emanuel wants to make Chicago more immigrant-friendly (Chicago Tribune)
- Emanuel acknowledges aldermen's complaints about rise in killings (Chicago Tribune)
- The Little Blue Book: Quotations from Chairman Lakoff (PJ Media)
You need to be a member of Patriot Action Network to add comments!
This reply was deleted.
Today's News
Latest Network Activity
For a minute there I thought this was breaking news - 100 year-old woman breaks record for 100 yard dash – was about Hillary clinching the Democrat nomination. Butt It wasn't even about the Democrats' 100 year old woman:It was about a real 100 year-…
This is it, election day in Indiana; a huge day for all who love our great country and desire not to see it continue to be transformed into something evil and unrecognizable. Our Conservative Campaign Committee team is still in Indiana campaigning f…
By Craig Andresen Right Side Patriots http://www.americanpbn.com/When it comes to trade, and trade deals, Trump's low-information following is all about their candidate's plans. They love his tough talk and his bloviations regarding China and Mexico…
I really didn't want to, butt in the end, curiosity got the better of me so I read the "White Fragility" article linked by dchrist81 yesterday.When you see an event titled Whiteness History Month at a college you can't expect it to be a celebration…
Heidi Cruz & Lloyd Marcus in Anderson INDon't you just hate early-morning phone calls from family? Our Conservative Campaign Committee team is in Indiana, campaigning for Ted Cruz. When I returned to our hotel room after picking up breakfast for m…
On display at last night's White House Correspondents Dinner were all the skills that landed Barry in office in the first place: a keen ability to deliver lines written by others in a convincing manner. Which just so happens to be the #1 requirement…
Joseph Goebbels said, "If you tell a lie big enough and keep repeating it, people will eventually come to believe it." While I realize that Goebbels was Hitler's propaganda minister, in no way am I comparing Trump's campaign to Hitler. Such compar…
The historic half-black American President. What has he done to help America? ANYTHING? ABSOLUTELY NOTHING! He has harmed America in innumerable ways, he has ruined the greatest healthcare system in the World, lied his way through his whole terms,…


text:
Christmas Mountains Wrapped in Holiday Colors
NASA Satellite Shows a Mean Irene's Fury
Ice Front at Venable Ice Shelf
Anaglyph with Landsat Overlay, Kamchatka Peninsula, Russia
Huaraz, Peru
Australian Wildfire, NASA Spacecraft Image Aftermath
Ogasawara Islands, Japan
Mapping Lunar Highlands
Hallstatt, Austria
ASTER Dunes
Stratified Arctic Clouds
NASA Satellite Tracks Texas-Bound Tropical Storm Don
Mouth of the Amazon
Poyang Lake, China
Earth Triptych from NASA's Juno Spacecraft
Jamestown, VA
Rice Cultivation in Northwest Italy
Yarlung Zangpo Grand Canyon, Tibet
SRTM Data Release for Africa, Colored Height
On the West Coast of the Ocean of Storms (Artist's Concept)
Where on Earth...? MISR Mystery Image Quiz #8: Yarlung Tsangpo River, China
Kizimen Volcano, Kamchatka
NASA Spacecraft Images Severe Flooding in South Asia
Anaglyph: Patagonia, Argentina
Antarctica - Ross Ice Shelf
Edinburgh, Scotland
Angry Ecuadorian Volcano Imaged by NASA Spacecraft
OPALS Thermal Vacuum Testing
OPALS Vibration Testing
Mawsynram, India
The Nile
NASA's MISR Views Raging Wildfires in Southeastern Montana
Where on Earth...? MISR Mystery Image Quiz #17: The Pampas of Argentina
NASA's ARIA Project Maps Deformation of Earth's Surface from Nepal Quake
NASA Soil Moisture Mission Produces First Global Radiometer Map
NASA Radar Image Shows Topography of Sendai, Japan Region
Three Gorges Dam, China
ASTER Washington, D.C.
Mars Researchers Rendezvous on Remote Arctic Island
Anaglyph, Mount St Helens, Washington State
Sand Dunes, Namibia
Jacking up the Antenna
Saturday Afternoon Swim
Ship Tracks in a Stratiform Cloud Layer
NASA's MISR Sees Cloud Heights at Top of Hurricane Irene
Sochi, Russia Winter Olympic Sites (Mountain Cluster)
Earth - Northeast Africa and the Arabian Peninsula
Where on Earth...? MISR Mystery Image Quiz #18: Normandy, Poitou, Bourgogne Regions, France
Dust Shrouds the Eastern Mediterranean


text:
The contract to construct the $10 million Central Australia Renal Accommodation project has been awarded to the Central Australian Affordable Housing Company (CAAHC).
The Western Australian government has awarded the contract to design, construct and maintain the Forrestfield-Airport Link.
The Queensland government and GoldLinQ have entered into a partnership to construct the Gold Coast light rail extension in time for the 2018 Commonwealth Games.
Queensland is set to construct the largest startup hub within Brisbane's Fortitude Valley for entrepreneurs.
The Victorian government has released the contract to construct the Melbourne Metro rail project.
The Victorian government has announced $61.3 million in infrastructure works for hospitals in Melbourne's West.
Coffs Harbour City Council has announced its decision to aim for 100% renewable energy for all council facilities by 2030.
Major works have begun on the $620 million Darlington Upgrade Project.
The Western Australian government has announced the completion of the $5.1 million Kununurra airstrip upgrade.
Works have commenced to construct two new bridges on the Roper Highway at the Wilton River and Roper River crossings.
A consortium of architects have been selected to redesign the State Library as part of the $83.1 million State Library Victoria Vision 2020 redevelopment.
The Western Australian government has installed eleven new automatic weather stations across the Grainbelt.


text:
Save the guy with the chair on his head!
PLEASE NOTE: A Journal Sentinel subscription is now required to comment. You can read more about that transition in our FAQ. As always, our discussion guidelines and terms of use still apply to all comments and commenters. If you have any issues logging in to or using our commenting system, please let us know.
- You can log in to this system either through Facebook or using your JSOnline public profile. JSOnline public profile. Please note that your public profile login will be different than your JS Everywhere login.
- You can personalize your public profile with a photo. You can also use that profile to sign up for email newsletters and alerts.
- While we strive for a lively and vigorous debate of the issues, we do not tolerate name calling, foul language or other inappropriate behavior. Please see our discussion guidelines and terms of use for more information.
- While we do our best to moderate comments, we do not screen comments before they are posted. If you see a comment that violates our guidelines, please use the "Report Abuse" link to notify us of the issue.
- We reserve the right to close commenting on specific stories.
And this is art how? Seriously, I've tiped chairs over dozens of times and no one ever thought it should be put into an art gallery.
One of the best pieces in the contemporary collection at MAM. Provocative, funny, unsettling, insightful, and extremely efficient at having such a powerful effect. In response to a previous post- it is "art how" because it enables viewers to become involved and enaged on several different levels. It is "art how" because it reflects back to us aspects of a world, sometimes ours, sometimes its own, and allows us an opportunity to think again about what we know. Not only what we know about art, artists, museums, but what we know of ourselves, our fears and dreams, both cliched and real. Yes- it does all of this, and I'm hardly in the minority to understand how this is art. How this is art is truly amazing.
If you prefer none of what this art does and prefer the company of mindless "talent" perhaps you can wait in anticipation for "Bronzie" who will stare back at you with that insipid smile of a has been actor, pigeon holed into a career stunting (pun intended) role, translated into a PR move so obviously and spectacularly ill conceived most likely by folks sitting around a conference table so desperately out of touch with contemporary culture. He'll be a poster child for ideas attempting to be hip, but so sorrowfully off the mark as to be the antithesis of what it's supposed to be. Cool? Everything but.
Wait, let me dumb all of that down for Bronzie's supporters in a format that seems fitting. Word scramble- Clue: Proposed sculpture of sitcom character for Milwaukee? Piel fo rapc.
A more glaring contrast couldn't be found. Anyway- it's nice that the Oursler has so many fans. Although rotating works is what museums do. It's sad to see a favorite go into storage, but with this much support perhaps it'll shorten it's vacation. There are other Oursler's out in the world to go experience and those works of this phase of his career are some of the best things he's done- so far.
- Milwaukee galleries do well at Art Basel Miami
- Dirk Skreber's exhibit at Milwaukee Art Museum captivates with catastrophe
- Too much testosterone at the Business Journal?
- Finalists named for public art project on W. Wisconsin Ave.
- Ten art books for art lovers this holiday season
- Art-inspired alternatives to Black Friday
- Art City Radio: Nicolas Lampert and Black Friday
- Art City Radio: Tag Milwaukee
- Nohl exhibit a mismatch for some fellowship winners' art
- Art City's weekend recommendations
Design Ideas is a weekly column exploring the many ways that design intersects our lives.
An ongoing series of interviews with creative people.
E-mail Newsletter
Keep up with the art scene and trends in urban design with art and architecture critic Mary Louise Schumacher. Every week, you'll get the latest reviews, musings on architecture and her picks for what to do on the weekends.
Enter your e-mail address above and click "Sign Up Now!" to begin receiving your e-mail newsletter Get the Newsletter!